Publications by authors named "Monika Jun"

Claim this Profile
R
Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma.
Loretta J Nastoupil, Clark R Andersen, Amy Ayers, Yucai Wang, Thomas M Habermann, Monika Jun

Clin Lymphoma Myeloma Leuk· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma.
Jennifer L Crombie, Monika Jun, Tongsheng Wang, Alex Mutebi, Anthony Wang

Leuk Lymphoma· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practice efficiency and total cost of care with bispecifics and CAR-T in relapsed/refractory diffuse large B-cell lymphoma: an institutional perspective.
Matthew Lei, Qianyi Li, Ken O'Day, Kellie Meyer, Anthony Wang, Monika P Jun

Future Oncol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns, healthcare resource utilization, and costs in Medicare patients with diffuse large B-cell lymphoma: a retrospective claims analysis (2015-2020).
Monika P Jun, Alex Mutebi, Anindit Chhibber, Chenxue Liang, Allison Keshishian

J Med Econ· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma.
Allison Rosenthal, Javier Munoz, Monika Jun, Tongsheng Wang, Alex Mutebi, Junhua Yu

J Hematol Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Outcomes with Standard of Care in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Real-World Data Analysis.
Andrew Ip, Alex Mutebi, Tongsheng Wang, Monika Jun, Anupama Kalsekar

Adv Ther· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States.
Scott J Keating, Tao Gu, Monika P Jun, Ali McBride

Transplant Cell Ther· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health State Utilities for Adverse Events Associated with Chimeric Antigen Receptor T-Cell Therapy in Large B-Cell Lymphoma.
Timothy A Howell, Louis S Matza, Monika P Jun, Jacob Garcia, Annette Powers

Pharmacoecon Open· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postinfusion monitoring costs by site of care for patients with relapsed/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials.
M Lia Palomba, Monika Parisi Jun, James Lymp, Andy Nguyen, November McGarvey

Leuk Lymphoma· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Access to Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma.
Sophie Snyder, Karen C Chung, Monika P Jun, Matthew Gitlin

Adv Ther· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Travel-Related Economic Burden of Chimeric Antigen Receptor T Cell Therapy Administration by Site of Care.
Sophie Snyder, Tina Albertson, Jacob Garcia, Matthew Gitlin, Monika P Jun

Adv Ther· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of lisocabtagene maraleucel on HRQoL and symptom severity in relapsed/refractory large B-cell lymphoma.
Donald L Patrick, Annette Powers, Monika Parisi Jun, Yeonhee Kim, Jacob Garcia

Blood Adv· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial.
Jeremy S Abramson, Tanya Siddiqi, Jacob Garcia, Christine Dehner, Yeonhee Kim, Monika P Jun

Blood Adv· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis